CBD Partially Blocks THC Metabolism in the Liver, With Women Showing Higher THC Blood Levels Than Men
A double-blind study of 24 volunteers found evidence that CBD partially inhibits the liver enzyme that converts THC to its active metabolite 11-OH-THC, though the effect was small compared to natural individual variation, and women had significantly higher THC blood levels than men.
Quick Facts
What This Study Found
Twenty-four volunteers (12 male, 12 female) received soft-gelatin capsules of either 10 mg THC alone, cannabis extract containing 10 mg THC plus 5.4 mg CBD, or placebo in a crossover design. Blood samples were collected over 24 hours and analyzed for THC, 11-OH-THC, THC-COOH, and CBD.
Despite large individual variation in the data, evidence emerged that CBD partially inhibits the CYP 2C enzyme that hydroxylates THC to 11-OH-THC. This inhibition is likely most relevant for oral intake because THC and CBD reach relatively high liver concentrations and because of THC's substantial first-pass metabolism.
However, the effect of CBD was small compared to variability from other factors. A notable secondary finding was that women had significantly higher peak concentrations (Cmax) and total exposure (AUC) of THC, and reached peak levels faster (shorter tmax) than men.
Key Numbers
24 volunteers (12 male, 12 female). Doses: 10 mg THC alone or 10 mg THC + 5.4 mg CBD. Blood sampled at 9 time points over 24 hours. CBD partially inhibits CYP 2C-mediated THC hydroxylation. Women had significantly higher Cmax and AUC for THC than men.
How They Did This
Double-blind, placebo-controlled, crossover study in 24 volunteers (12 male, 12 female, age 18-45). Three conditions at weekly intervals: 10 mg THC capsules, cannabis extract (10 mg THC + 5.4 mg CBD), or placebo. Blood samples at 9 time points over 24 hours. THC and metabolites measured by solid phase extraction, derivatization, and GC-MS. Pharmacokinetic parameters compared statistically.
Why This Research Matters
The finding that CBD partially inhibits THC metabolism has implications for dosing cannabis-based medicines. If CBD reduces THC conversion to its active metabolite, the ratio of THC to CBD in a product could affect the pharmacological profile. The sex difference finding also suggests men and women may need different dosing considerations.
The Bigger Picture
Understanding how CBD affects THC metabolism is critical for developing standardized cannabis-based medicines. This study provides pharmacokinetic evidence that the THC-to-CBD ratio matters not just for pharmacodynamic (receptor-level) interactions but also for how the body processes THC. The sex difference finding adds another layer of complexity to cannabis dosing.
What This Study Doesn't Tell Us
Large individual variation in pharmacokinetic data made it difficult to detect definitive effects. The doses used (10 mg THC, 5.4 mg CBD) may not represent all clinical scenarios. The study concluded the pharmacokinetic interaction is unlikely to explain clinical differences between pure THC and cannabis extract at these doses. Only single-dose pharmacokinetics were assessed.
Questions This Raises
- ?At what CBD-to-THC ratios does the metabolic inhibition become clinically significant?
- ?Should dosing recommendations for cannabis-based medicines differ between men and women?
Trust & Context
- Key Stat:
- Women had significantly higher THC blood levels (Cmax and AUC) and faster absorption than men
- Evidence Grade:
- Well-designed double-blind, placebo-controlled crossover study with rigorous pharmacokinetic analysis. Adequate sample size for pharmacokinetic work. High individual variability limited definitive conclusions.
- Study Age:
- Published in 2005. Understanding of CBD-THC pharmacokinetic interactions has advanced since then, with more studies examining different dose ratios and delivery methods.
- Original Title:
- Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
- Published In:
- Therapeutic drug monitoring, 27(6), 799-810 (2005)
- Authors:
- Nadulski, Thomas(3), Pragst, Fritz, Weinberg, Gordon, Roser, Patrik, Schnelle, Martin, Fronk, Eva-Maria, Stadelmann, Andreas Michael
- Database ID:
- RTHC-00199
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does CBD change how the body processes THC?
This study found evidence that CBD partially inhibits the liver enzyme (CYP 2C) responsible for converting THC to its active metabolite 11-OH-THC. This effect is most relevant when both are taken orally, as they pass through the liver. However, the effect was small compared to natural individual variation.
Do men and women process THC differently?
Yes. Women in this study had significantly higher peak THC concentrations and total THC exposure than men given the same dose, and reached peak levels faster. This suggests biological sex affects THC pharmacokinetics and may be relevant for dosing.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-antibiotics-safe-cannabis-while-on
- thc-and-caffeine-most-common-drug-combo
- thc-and-diabetes-medication-blood-sugar
Cite This Study
https://rethinkthc.com/research/RTHC-00199APA
Nadulski, Thomas; Pragst, Fritz; Weinberg, Gordon; Roser, Patrik; Schnelle, Martin; Fronk, Eva-Maria; Stadelmann, Andreas Michael. (2005). Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.. Therapeutic drug monitoring, 27(6), 799-810.
MLA
Nadulski, Thomas, et al. "Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.." Therapeutic drug monitoring, 2005.
RethinkTHC
RethinkTHC Research Database. "Randomized, double-blind, placebo-controlled study about the..." RTHC-00199. Retrieved from https://rethinkthc.com/research/nadulski-2005-randomized-doubleblind-placebocontrolled-study
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.